Hypertension is a frequently observed AE associated with VEGF inhibitors21 and is commonly reported in ramucirumab clinical trials.4-8 Our analysis revealed no obvious differences in the risk of hypertension in the ramucirumab arm between EA and non-EA patients (23% EA v 21% non-EA patients). The gene discussed is VEGFA; the disease is Hypertension.